Source: http://www.google.es/patents/US20030078623?dq=flatulence
Timestamp: 2016-04-29 23:34:06
Document Index: 772263554

Matched Legal Cases: ['art 102', 'art 102', 'art 102', 'art 102', 'art 102', 'art 102']

Patente US20030078623 - Implantable lead and method for stimulating the vagus nerve - Google PatentesB�squeda Im�genes Maps Play YouTube Noticias Gmail Drive M�s »Iniciar sesi�nPatentesMethods and apparatus for stimulating the right vagal nerve within a living body via positioning an electrode portion of a lead proximate to the portion of the vagus nerve where the right cardiac branch is located (e.g., near or within an azygos vein, or the superior vena cava near the opening of the...http://www.google.es/patents/US20030078623?utm_source=gb-gplus-sharePatente US20030078623 - Implantable lead and method for stimulating the vagus nerve B�squeda avanzada de patentes N�mero de publicaci�nUS20030078623 A1Tipo de publicaci�nSolicitud N�mero de solicitudUS 10/000,333 Fecha de publicaci�n24 Abr 2003 Fecha de presentaci�n22 Oct 2001 Fecha de prioridad22 Oct 2001Tambi�n publicado comoEP1304135A2, EP1304135A3, US6934583 N�mero de publicaci�n000333, 10000333, US 2003/0078623 A1, US 2003/078623 A1, US 20030078623 A1, US 20030078623A1, US 2003078623 A1, US 2003078623A1, US-A1-20030078623, US-A1-2003078623, US2003/0078623A1, US2003/078623A1, US20030078623 A1, US20030078623A1, US2003078623 A1, US2003078623A1 InventoresLisa Weinberg, Paul Levine Cesionario originalWeinberg Lisa P., Levine Paul A.Exportar citaBiBTeX, EndNote, RefManCitas de patentes (1), Citada por (319), Clasificaciones (8), Eventos legales (3) Enlaces externos: USPTO, Cesi�n de USPTO, EspacenetImplantable lead and method for stimulating the vagus nerve
US 20030078623 A1 Resumen
Methods and apparatus for stimulating the right vagal nerve within a living body via positioning an electrode portion of a lead proximate to the portion of the vagus nerve where the right cardiac branch is located (e.g., near or within an azygos vein, or the superior vena cava near the opening of the azygos vein) and delivering an electrical signal to an electrode portion adapted to be implanted therein. Stimulation of the right vagus nerve and/or the cardiac branch thereof act to slow the atrial heart rate. Exemplary embodiments include deploying an expandable or self-oriented electrode (e.g., a basket, an electrode umbrella, and/or an electrode spiral electrode, electrode pairs, etc). Various dedicated and single-pass leads are disclosed, as well as, various electrodes, and stabilization means. The methods include preserving sinus rhythm, avoiding asystole, preserving A-V synchrony, automatically determining parameter combinations that achieve these features, and further (in one embodiment) automatically determining parameter combinations achieve these features and reduce current drain. Im�genes(20) Reclamaciones(33)
DETAILED DESCRIPTION [0054] The following description is of the best mode presently contemplated for practicing the described implementations. This description is not to be taken in a limiting sense, but rather is made merely for the purpose of describing the general principles of the implementations. The scope of the described implementations should be ascertained with reference to the issued claims. In the description that follows, like numerals or reference designators will be used to reference like parts or elements throughout. [0055] Exemplary Stimulation Device [0056] The techniques described below are intended to be implemented in connection with any stimulation device that is configured or configurable to stimulate or shock a patient's heart. [0057] [0057]FIG. 1 shows an exemplary stimulation device 100 in electrical communication with a patient's heart 102 by way of three electrical “connections” 104, 106, and 108, suitable for delivering multi-chamber stimulation and shock therapy. While two of the electrical connections (104 and 108) are shown as a single-pass lead, since the present invention is directed in some embodiments towards an improved single-pass lead, it is to be understood that individual leads could also be used to describe the fundamentals of multi-chamber stimulation. Accordingly, the term electrical “connections” will be used herein to describe the system that makes contact with an electrode, whether it is by a single-pass lead or an individual lead. [0058] To sense atrial cardiac signals and to provide right atrial chamber stimulation therapy, stimulation device 100 is coupled to an implantable right atrial electrical connection 104, coupled to at least an atrial tip electrode 120 and optionally an atrial ring electrode 121, which typically is implanted in the patient's right atrial appendage. [0059] Stimulation device 100 is also shown in electrical communication with the patient's heart 102 by way of an implantable right ventricular connection 108 having, in this implementation, a right ventricular tip electrode 128, a right ventricular ring electrode 130, a right ventricular (RV) coil electrode 132, and an SVC coil electrode 134. Accordingly, the right ventricular connection 108 is capable of sensing or receiving cardiac signals, and delivering stimulation in the form of pacing and shock therapy to the right ventricle. [0060] To sense left atrial and ventricular cardiac signals and to provide left chamber pacing therapy, stimulation device 100 is coupled to a single-pass coronary sinus connection 106, that is, a lead designed for placement in the coronary sinus region via the coronary sinus for positioning a distal electrode adjacent to the left ventricle and/or additional electrode(s) adjacent to the left atrium. As used herein, the phrase “coronary sinus region” refers to the vasculature of the left ventricle, including any portion of the coronary sinus, great cardiac vein, left marginal vein, left posterior ventricular vein, middle cardiac vein, and/or small cardiac vein or any other cardiac vein accessible by the coronary sinus. [0061] Accordingly, an exemplary coronary sinus connection 106 is designed to receive atrial and ventricular cardiac signals and to deliver left ventricular pacing therapy using at least a left ventricular tip electrode 122, left atrial pacing therapy using at least a left atrial ring electrode 124, and shocking therapy using, for example a left atrial coil electrode 126 (or a left ventricular coil electrode, not shown, or both). For a complete description of a coronary sinus lead, the reader is directed to U.S. patent application Ser. No. 09/457,277, filed Dec. 8, 1999, entitled “A Self-Anchoring, Steerable Coronary Sinus Lead” (Pianca et. al), which patent is hereby incorporated herein by reference. [0062] [0062]FIG. 2 shows an exemplary, simplified block diagram depicting various components of stimulation device 100. The stimulation device 100 can be capable of treating both fast and slow arrhythmias with stimulation therapy, including cardioversion, defibrillation, and pacing stimulation. While a particular multi-chamber device is shown, it is to be appreciated and understood that this is done for illustration purposes only. Thus, the techniques and methods described below can be implemented in connection with any suitably configured or configurable stimulation device. Accordingly, one of skill in the art could readily duplicate, eliminate, or disable the appropriate circuitry in any desired combination to provide a device capable of treating the appropriate chamber(s) with cardioversion, defibrillation, and pacing stimulation. [0063] Housing 200 for stimulation device 100 is often referred to as the “can”, “case” or “case electrode”, and may be programmably selected to act as the return electrode for all “unipolar” modes. Housing 200 may further be used as a return electrode alone or in combination with one or more of the coil electrodes 126, 132 and 134 for shocking purposes. Housing 200 further includes a connector (not shown) having a plurality of terminals 202, 204, 206, 208, 212, 214, 216, and 218 (shown schematically and, for convenience, the names of the electrodes to which they are connected are shown next to the terminals). [0064] To achieve right atrial sensing and pacing, the connector includes at least a right atrial tip terminal (AR TIP) 202 adapted for connection to the atrial tip electrode 120. To achieve left chamber sensing, pacing, and shocking, the connector includes at least a left ventricular tip terminal (VL TIP) 204, a left atrial ring terminal (AL RING) 206, and a left atrial shocking terminal (AL COIL) 208, which are adapted for connection to the left ventricular tip electrode 122, the left atrial ring electrode 124, and the left atrial coil electrode 126, respectively. [0065] To support right chamber sensing, pacing, and shocking, the connector further includes a right ventricular tip terminal (VR TIP) 212, a right ventricular ring terminal (VR RING) 214, a right ventricular shocking terminal (RV COIL) 216, and a superior vena cava shocking terminal (SVC COIL) 218, which are adapted for connection to the right ventricular tip electrode 128, right ventricular ring electrode 130, the RV coil electrode 132, and the SVC coil electrode 134, respectively. [0066] At the core of the stimulation device 100 is a programmable microcontroller 220 that controls the various modes of stimulation therapy. As is well known in the art, microcontroller 220 typically includes a microprocessor, or equivalent control circuitry, designed specifically for controlling the delivery of stimulation therapy, and may further include RAM or ROM memory, logic and timing circuitry, state machine circuitry, and I/O circuitry. Typically, microcontroller 220 includes the ability to process or monitor input signals (data or information) as controlled by a program code stored in a designated block of memory. The type of microcontroller is not critical to the described implementations. Rather, any suitable microcontroller 220 may be used that carries out the functions described herein. The use of microprocessor-based control circuits for performing timing and data analysis functions are well known in the art. [0067] [0067]FIG. 2 also shows an atrial pulse generator 222 and a ventricular pulse generator 224 that generate pacing stimulation pulses for delivery by the right atrial connection 104, the coronary sinus connection 106, and/or the right ventricular connection 108 via an electrode configuration switch 226. It is understood that in order to provide stimulation therapy in each of the four chambers of the heart, the atrial and ventricular pulse generators, 222 and 224, may include dedicated, independent pulse generators, multiplexed pulse generators, or shared pulse generators. The pulse generators 222 and 224 are controlled by the microcontroller 220 via appropriate control signals 228 and 230, respectively, to trigger or inhibit the stimulation pulses. [0068] Microcontroller 220 further includes timing control circuitry 232 to control the timing of the stimulation pulses (e.g., pacing rate, atrio-ventricular (AV) delay, atrial interconduction (A-A) delay, or ventricular interconduction (V-V) delay, etc.) as well as to keep track of the timing of refractory periods, blanking intervals, noise detection windows, evoked response windows, alert intervals, marker channel timing, etc., which is well known in the art. [0069] Microcontroller 220 further includes an arrhythmia detector 234, a morphology detector 236, and optionally an orthostatic compensator and a minute ventilation (MV) response module, the latter two are not shown in FIG. 2. These components can be utilized by the stimulation device 100 for determining desirable times to administer various therapies, including those to reduce the effects of orthostatic hypotension. The aforementioned components may be implemented in hardware as part of the microcontroller 220, or as software/firmware instructions programmed into the device and executed on the microcontroller 220 during certain modes of operation. [0070] Microcontroller 220 further includes a vagal module 238 for performing a variety of tasks related to vagal stimulation. This component can be utilized by the stimulation device 100 for determining desirable times to administer various therapies, including timing, frequency of pulse trains, amplitude and pulse duration for vagal stimulation in order to control heart rate. The vagal module 238 may be implemented in hardware as part of the microcontroller 220, or as software/firmware instructions programmed into the device and executed on the microcontroller 220 during certain modes of operation. [0071] The electronic configuration switch 226 includes a plurality of switches for connecting the desired electrodes to the appropriate I/O circuits, thereby providing complete electrode programmability. Accordingly, switch 226, in response to a control signal 242 from the microcontroller 220, determines the polarity of the stimulation pulses (e.g., unipolar, bipolar, combipolar, etc.) by selectively closing the appropriate combination of switches (not shown) as is known in the art. [0072] Atrial sensing circuits 244 and ventricular sensing circuits 246 may also be selectively coupled to the right atrial connection 104, coronary sinus connection 106, and the right ventricular connection 108, through the switch 226 for detecting the presence of cardiac activity in each of the four chambers of the heart. Accordingly, the atrial (ATR. SENSE) and ventricular (VTR. SENSE) sensing circuits, 244 and 246, may include dedicated sense amplifiers, multiplexed amplifiers, or shared amplifiers. Switch 226 determines the “sensing polarity” of the cardiac signal by selectively closing the appropriate switches, as is also known in the art. In this way, the clinician may program the sensing polarity independent of the stimulation polarity. The sensing circuits (e.g., 244 and 246) are optionally capable of obtaining information indicative of tissue capture. [0073] Each sensing circuit 244 and 246 preferably employs one or more low power, precision amplifiers with programmable gain and/or automatic gain control, bandpass filtering, and a threshold detection circuit, as known in the art, to selectively sense the cardiac signal of interest. The automatic gain control enables the device 100 to deal effectively with the difficult problem of sensing the low amplitude signal characteristics of atrial or ventricular fibrillation. [0074] The outputs of the atrial and ventricular sensing circuits 244 and 246 are connected to the microcontroller 220, which, in turn, is able to trigger or inhibit the atrial and ventricular pulse generators 222 and 224, respectively, in a demand fashion in response to the absence or presence of cardiac activity in the appropriate chambers of the heart. [0075] Furthermore, as described herein, the microcontroller 220 is also capable of analyzing information output from the sensing circuits 244 and 246 and/or the data acquisition system 252 to determine or detect whether and to what degree tissue capture has occurred and to program a pulse, or pulses, in response to such determinations. The sensing circuits 244 and 246, in turn, receive control signals over signal lines 248 and 250 from the microcontroller 220 for purposes of controlling the gain, threshold, polarization charge removal circuitry (not shown), and the timing of any blocking circuitry (not shown) coupled to the inputs of the sensing circuits, 244 and 246, as is known in the art. [0076] For arrhythmia detection, the device 100 utilizes the atrial and ventricular sensing circuits, 244 and 246, to sense cardiac signals to determine whether a rhythm is physiologic or pathologic. In reference to arrhythmias, as used herein, “sensing” is reserved for the noting of an electrical signal or obtaining data (information), and “detection” is the processing (analysis) of these sensed signals and noting the presence of an arrhythmia. The timing intervals between sensed events (e.g., P-waves, R-waves, and depolarization signals associated with fibrillation which are sometimes referred to as “F-waves” or “Fib-waves”) are then classified by the arrhythmia detector 234 of the microcontroller 220 by comparing them to a predefined rate zone limit (i.e., bradycardia, normal, low rate VT, high rate VT, and fibrillation rate zones) and various other characteristics (e.g., sudden onset, stability, physiologic sensors, and morphology, etc.) in order to determine the type of remedial therapy that is needed (e.g., bradycardia pacing, anti-tachycardia pacing, cardioversion shocks or defibrillation shocks, collectively referred to as “tiered therapy”). [0077] Cardiac signals are also applied to inputs of an analog-to-digital (A/D) data acquisition system 252. The data acquisition system 252 is configured to acquire intracardiac electrogram signals, convert the raw analog data into a digital signal, and store the digital signals for later processing and/or telemetric transmission to an external device 254. The data acquisition system 252 is coupled to the right atrial connection 104, the coronary sinus connection 106, and the right ventricular connection 108 through the switch 226 to sample cardiac signals across any pair of desired electrodes. [0078] The microcontroller 220 is further coupled to a memory 260 by a suitable data/address bus 262, wherein the programmable operating parameters used by the microcontroller 220 are stored and modified, as required, in order to customize the operation of the stimulation device 100 to suit the needs of a particular patient. Such operating parameters define, for example, pacing pulse amplitude, pulse duration, electrode polarity, rate, sensitivity, automatic features, arrhythmia detection criteria, and the amplitude, waveshape and vector of each shocking pulse to be delivered to the patient's heart 102 within each respective tier of therapy. One feature of the described embodiments is the ability to sense and store a relatively large amount of data (e.g., from the data acquisition system 252), which data may then be used for subsequent analysis to guide the programming of the device. [0079] Advantageously, the operating parameters of the implantable device 100 may be non-invasively programmed into the memory 260 through a telemetry circuit 264 in telemetric communication via communication link 266 with the external device 254, such as a programmer, transtelephonic transceiver, or a diagnostic system analyzer. The microcontroller 220 activates the telemetry circuit 264 with a control signal 268. The telemetry circuit 264 advantageously allows intracardiac electrograms and status information relating to the operation of the device 100 (as contained in the microcontroller 220 or memory 260) to be sent to the external device 254 through an established communication link 266. [0080] The stimulation device 100 can further include a physiologic sensor 270, commonly referred to as a “rate-responsive” sensor because it is typically used to adjust pacing stimulation rate according to the exercise state of the patient. However, the physiological sensor 270 may further be used to detect changes in cardiac output, changes in the physiological condition of the heart, or diurnal changes in activity (e.g., detecting sleep and wake states). Accordingly, the microcontroller 220 responds by adjusting the various pacing parameters (such as rate, AV Delay, V-V Delay, etc.) at which the atrial and ventricular pulse generators, 222 and 224, generate stimulation pulses. In the present invention, physiologic sensors may be optionally utilized to confirm hemodynamic improvement following vagal stimulation. [0081] While shown as being included within the stimulation device 100, it is to be understood that the physiologic sensor 270 may also be external to the stimulation device 100, yet still be implanted within or carried by the patient. Examples of physiologic sensors that may be implemented in device 100 include known sensors that, for example, sense respiration rate, pH of blood, ventricular gradient, and so forth. Another sensor that may be used is one that detects activity variance, wherein an activity sensor is monitored diurnally to detect the low variance in the measurement corresponding to the sleep state. [0082] More specifically, the physiological sensors 270 optionally include sensors for detecting movement and minute ventilation in the patient. The physiological sensors 270 may include a position sensor and/or a minute ventilation (MV) sensor to sense minute ventilation, which is defined as the total volume of air that moves in and out of a patient's lungs in a minute. Signals generated by the position sensor and MV sensor are passed to the microcontroller 220 for analysis in determining whether to adjust the pacing rate, etc. The microcontroller 220 monitors the signals for indications of the patient's position and activity status, such as whether the patient is climbing upstairs or descending downstairs or whether the patient is sitting up after lying down. [0083] The stimulation device additionally includes a battery 276 that provides operating power to all of the circuits shown in FIG. 2. For the stimulation device 100, which employs shocking therapy, the battery 276 is capable of operating at low current drains for long periods of time (e.g., preferably less than 10 μA), and is capable of providing high-current pulses (for capacitor charging) when the patient requires a shock pulse (e.g., preferably, in excess of 2 A, at voltages above 2 V, for periods of 10 seconds or more). The battery 276 also desirably has a predictable discharge characteristic so that elective replacement time can be detected. Accordingly, the device 100 employs a lithium iodide and/or silver vanadium oxide batteries. [0084] The stimulation device 100 can further include magnet detection circuitry (not shown), coupled to the microcontroller 220, to detect when a magnet is placed over the stimulation device 100 to perform various test functions of the stimulation device 100 and/or to receive or transmit data to the microcontroller 220 through the telemetry circuits 264. [0085] The stimulation device 100 further includes an impedance measuring circuit 278 that is enabled by the microcontroller 220 via a control signal 280. The known uses for an impedance measuring circuit 278 include, but are not limited to, lead impedance surveillance during the acute and chronic phases for proper lead positioning or dislodgment; detecting operable electrodes and automatically switching to an operable pair if dislodgment occurs; measuring respiration or minute ventilation; measuring thoracic impedance for determining shock thresholds; detecting when the device has been implanted; measuring stroke volume; and detecting the opening of heart valves, etc. The impedance measuring circuit 278 is advantageously coupled to the switch 226 so that any desired electrode may be used. [0086] In the case where the stimulation device 100 is intended to operate as an implantable cardioverter/defibrillator (ICD) device, it detects the occurrence of an arrhythmia, and automatically applies an appropriate therapy to the heart aimed at terminating the detected arrhythmia. To this end, the microcontroller 220 further controls a shocking circuit 282 by way of a control signal 284. The shocking circuit 282 generates shocking pulses of low (up to 0.5 J), moderate (0.5 J to 10 J), or high energy (11 J to 40 J), as controlled by the microcontroller 220. Such shocking pulses are applied to the patient's heart 102 through at least two shocking electrodes, and as shown in this embodiment, selected from the left atrial coil electrode 126, the RV coil electrode 132, and/or the SVC coil electrode 134. As noted above, the housing 200 may act as an active electrode in combination with the RV electrode 132, or as part of a split electrical vector using the SVC coil electrode 134 or the left atrial coil electrode 126 (i.e., using the RV electrode as a common electrode). [0087] Cardioversion level shocks are generally considered to be of low to moderate energy level (so as to minimize pain felt by the patient), and/or synchronized with an R-wave and/or pertaining to the treatment of tachycardia. Defibrillation shocks are generally of moderate to high energy level (i.e., corresponding to thresholds in the range of 5 J to 40 J), delivered asynchronously (since R-waves may be too disorganized), and pertaining exclusively to the treatment of fibrillation. Accordingly, the microcontroller 220 is capable of controlling the synchronous or asynchronous delivery of the shocking pulses. [0088] While the present invention may be employed in a system that provides cardioversion and defibrillation therapy, it may also be used in a system that only provide vagal stimulation to treat fast arrhythmias together with bradycardia support, i.e., in a pacemaker device. [0089] Anatomy [0090] Referring to FIG. 3, a heart 102 and a right vagus nerve 180 are shown. FIG. 3 also shows part of an azygos vein 170, particularly the portion that forms at least part of the “azygos arch” and connects with the heart's superior vena cava 160. The juncture or opening 174 between the azygos vein 170 and the superior vena cava 160 may be considered the end of the azygos vein, where deoxygenated blood enters the superior vena cava 160 en route to the heart's right atrium 164. The azygos vein 170 begins at the union of the right subcostal vein and the right ascending lumbar vein. The azygos vein 170 enters the thorax by passing through the aortic hiatus or by passing through or behind the right crus of the diaphragm. The azygos vein 170 passes upward through the posterior mediastinum near the midline just anterior to the bodies of the thoracic vertebrae or slightly to the right side of the vertebral bodies. At the level of the fourth thoracic vertebra the azygos vein 170 arches anteriorly over the root structures of the right lung to drain into the superior vena cava 160 usually just above the point where the superior vena cava 160 penetrates the pericardium. As the azygos vein 170 passes upward through the posterior mediastinum it lies just to the right of the thoracic duct which is just to the right of the descending aorta. [0091] The hemiazygos vein (not shown) begins at the union of the left ascending lumbar vein and the left subcostal vein. It passes upward into the thorax through the left crus of the diaphragm or through the aortic hiatus. It receives the caudal three or four left posterior intercostal veins and crosses the midline at about the level of the ninth thoracic vertebra to drain into the azygos vein 170. As it crosses the midline it passes dorsal to the aorta, the esophagus and the thoracic duct. [0092] [0092]FIG. 3 also shows a general depiction of the heart's aortic arch 168. The aortic arch 168 passes backwards and to the left behind the right half of the munubrium. Crossing the aortic arch 168 anterolaterally are the left phrenic, left vagus, left vagal cardiac branch and left sympathetic cardiac branch (not shown). As the left vagus reaches the inferior border of the aortic arch 168 it gives off the left recurrent laryngeal nerve, which passes backwards around the ligamentum arteriosum, to ascend between the trachea and esophagus. The upper part of the aortic arch 168 gives rise to the brachiocephalic trunk, left common carotid and left subclavian arteries. [0093] Referring again to FIG. 3, the right vagus nerve 180 descends along the innominate artery 166 (also known as the brachiocephalic trunk) and passes medial to the arch of the azygos vein 170 to lie on the right of the trachea. The right vagus nerve 180 also gives rise to a cardiac nerve branch 184 supplying the heart 102. This branch 184 forms a plexus located between the aortic arch 168 and the bifurcation of the trachea. Thus, the right vagus cardiac nerve branch 184 (and/or plexus) passes proximate to the azygos vein 170, in particular, proximate to the arch of the azygos vein 170. [0094] A posterior illustration of the general anatomy of the aforementioned region appears in FIG. 4. As shown in FIG. 4, the arch of the azygos vein 170 arches over the right bronchus 192 near the bifurcation of the trachea 190. The trachea 190 bifurcates into a right bronchus 192 and a left bronchus 194. Not shown in FIG. 4 are the innominate artery 166 and the right branch of the pulmonary artery, which is medial to the right bronchus 192 and the superior vena cava 160 and anterior to the right vagus nerve 180. [0095] While variation in anatomy typically occurs from one patient to another, the right innominate and the left innominate vein join together and meet the superior vena cava 160 at a vertical point approximately equal to the vertical point where the innominate artery 166 exits the aortic arch 168. From the superior vena cava 160, the left innominate vein passes anterior to the innominate artery 166, in a direction away from the right vagus nerve 180 and towards the left vagus nerve (not shown). As mentioned, the left vagus nerve crosses the aortic arch 168 anterolaterally whereas the right vagus nerve 180 passes posterior to the aortic arch 168 and hence, generally does not contact the surface of the left innominate vein. [0096] For purposes of this discussion, it is the right vagus nerve that is of interest as it is believed to be controlling the Sinus Node and atrial rate, in general, whereas the left vagus nerve is believed to have a greater influence on the A-V Node. [0097] Thus, an exemplary method presented herein includes positioning a lead having at least one electrode in a patient's azygos vein proximate to the right vagus nerve and preferably near the cardiac branch; and stimulating the patient's right vagus nerve and/or right vagal cardiac branch using the at least one electrode. Several exemplary leads are presented herein that include at least one electrode for positioning in a patient's azygos vein and stimulating the patient's right vagus nerve and/or right vagal cardiac branch. [0098] In instances where an azygos vein portion of the lead includes a plurality of electrodes, positioning portions and/or features alleviate the need for selecting an electrode, or electrodes, amongst the plurality of electrodes to provide for adequate right vagus nerve stimulation. [0099] Leads [0100] FIGS. 5-10 shows six exemplary leads having at least one electrode capable of stimulating a patient's vagus nerve, respectively. Some of these six leads share various features with the leads presented in FIG. 1 and are suitable for use with the device 100 described with reference to FIG. 2. [0101] In particular, the leads shown in FIGS. 5-10 include, in various combinations of connections similar to those presented in FIG. 1, e.g., such as, the right atrial connection 104, the coronary sinus connection 106, and/or the right ventricular connection 108. However, leads shown in FIGS. 5-10 further include a vagal connection 110, that is, a conductor and electrode(s) suitable for stimulating the vagus nerve. [0102] For example, FIG. 5 is a dedicated vagal stimulation lead 310 having a vagal connection 110 (i.e., a proximal connector coupled to a conductor) for electrical contact with a deployable electrode (e.g., a basket electrode in this embodiment), and a distal end 408 having a stabilizing tail portion 414, as described in more complete detail in conjunction with FIG. 11. [0103] [0103]FIG. 6 is a dedicated right atrial lead 310 forming an conventional atrial-J configuration suitable for making contact to the right atrial connection 104 (i.e., a proximal connector coupled to a conductor) in addition to a vagal connection 110 (i.e., shown here for simplicity as a separate proximal connector coupled to a conductor). As shown in this embodiment, the vagal connection 110 is coupled to a deployable electrode (e.g., a basket electrode in this embodiment), and a distal end 408 without the stabilizing tail portion, as described in more complete detail in conjunction with FIG. 12, which instead continues “in-line” to form the distal end of the lead body where a conventional atrial electrode is attached. [0104] [0104]FIG. 7 illustrates a single-pass A-V lead 320 that combines the functions of the right atrial connection 104 and the left ventricular connection 108, and further adds a vagal connection 110 (i.e., shown here for simplicity as a separate proximal connectors coupled to a respective conductor). As shown in this embodiment, the vagal connection 110 is coupled to a deployable electrode (e.g., a basket electrode in this embodiment), and a distal end 408 with the stabilizing tail portion 414 (FIG. 12), and further includes atrial and ventricular pacing and sensing support using at least one ventricular electrode (128, 130, or both) and at least one atrial electrode (120, 121 or both). The advantages of the embodiment is that is supports A-V sensing, which is valuable for monitoring A-V dissociation (e.g., a partial or total interruption of the conduction from the atria to the ventricle, including prolongation of A-V conduction, first degree block (Mobitz I), second degree block (Mobitz II), or third degree A-V block) during vagal stimulation, as will be described in conjunction with the method steps in FIGS. 21-24 [0105] [0105]FIG. 8 illustrates a single-pass lead that combines the functions of the right atrial connection 104 and the left ventricular connection 108, with an “in-line” vagal connection 110. As shown in this embodiment, the vagal connection 110 is coupled to a deployable electrode (e.g., a basket electrode in this embodiment), and a distal end 408 (FIG. 11), which continues “in-line” to form at least one ventricular electrode (128, 130, or both) and at least one atrial electrode (120, 121 or both). In this embodiment, lead body between the atrial electrode 120 and the vagal electrode 400 (not shown to scale) may be configured to provide sufficient slack, or an atrial-J type shape, to allow placement of the atrial electrode 120 and further to allow the vagal electrode to be deployed against the SVC wall in a desired region near, or proximate, to the cardiac branch which will achieve a desired rate reduction by vagal stimulation. [0106] [0106]FIG. 9 illustrates yet another single-pass lead that combines the functions of the right atrial connection 104 and the left ventricular connection 108, with an “in-line” vagal connection 110. As shown in this embodiment, the atrial electrodes are shown as being conventional “in-line” ring electrodes (123, 125). [0107] [0107]FIG. 10 illustrates a single-pass coronary sinus lead 350 that combines the functions of the coronary sinus connection 106 with a vagal connection 110. As shown in this embodiment, the vagal connection 1 10 is coupled to a deployable electrode (e.g., a basket electrode in this embodiment), and a distal end 408 having a stabilizing tail portion 416 in the shape of an “S” wiggle (as shown described in conjunction with FIG. 13). The lead 350 continues “in-line” to form at least one ventricular electrode (122, 127, or both) and optionally at least one atrial electrode (126, 129 or both). From the above description of the leads shown in FIGS. 6 and 8, it is within the spirit of the invention to include a vagal electrode to be deployed “in-line” against the SVC wall in a desired region near, or proximate, to the cardiac branch to also achieve the desired rate reduction by vagal stimulation. [0108] While specific electrode combinations are shown, it is also within the spirit of the invention to add ring or coil electrodes in the atrium, or ventricle, or both and return electrodes in the SVC, as desired, to enhance tachyarrythmia therapy. [0109] While specific stabilization techniques have been shown, a lead may include any stabilization technique, such as, a hook, a tine, a spiral and/or a wiggle for securing the lead in a vessel by actively or passively fixating or otherwise biasing against the vessel to anchor the lead into position. For example, a preformed “S” wiggle (such as the one disclosed in the U.S. patent application Ser. No. 09/457,254, previously incorporated by reference above) can secure a lead within a vessel by applying a force to bias against the vessel. The leads described herein optionally include at least one hook, tine, spiral, and/or wiggle. [0110] FIGS. 11-15 show exemplary deployable or expandable electrode portions (400, 410, 415, 420, 440) suitable for use in the azygos vein. More specifically, the electrode portions (400, 420, 440) include a proximal portion (404, 424, 444) and a distal portion (408, 428, 448). Substantially positioned between the proximal portion (404, 424, 444) and the distal portion (408, 428, 448) is at least one electrode (416, 436, 456). Optionally, a shaft (412, 432, 452) may exist between the proximal or distal end to provide structural support. Alternatively, the electrodes (416, 436, 456) may be pre-shaped to attain their expanded state without a shaft. [0111] The electrode portion 400 shown in FIGS. 11-13 includes an electrode “basket” 416 or “basket electrode”, which optionally includes more than one electrode. The basket electrode may be a length of exposed conductor, or individually placed electrodes, or an array of electrodes, as shown and described in U.S. Pat. Nos. 5,782,239 and 5,411,025, which patents are hereby incorporated by reference in their entirety. In one embodiment using the “side-arm” configuration (e.g., FIG. 7) in which the vagal electrode is place in the azygos vein rather than “inline” near the SVC, an array of electrodes can be oriented or concentrated to face toward the tissue proximate to the cardiac branch. Upon implantation of such a lead, the side-arm and array of electrodes would self-orient towards the appropriate tissue. [0112] Several methods, well known in the art, may be used to deploy the electrode portion. For example a stylet may be used to position the lead body into position and upon remove, the electrode will expand to its preformed shape. Alternately, a guiding sheath, or pull wire, may be used. For example, U.S. Pat. no. 5,411,025 discloses an outer catheter or sheath that holds the basket in its undeployed state during implant. U.S. Pat. No. 5,782,239 also discloses a puller wire which causes the basket to extend to its fully deployed state. These patents have already been incorporated herein by reference above. Balloon mechanisms/methods, expansion mechanisms/methods for expanding and/or securing leads are also known to one of ordinary skill in the art. [0113] The electrode portion 420 shown in FIG. 14 includes an electrode “umbrella” 436 or “umbrella electrode”, which optionally also includes more than one electrode (e.g., exposed conductors or an electrode array disposed thereon). [0114] The electrode portion 440 shown in FIG. 15 includes an electrode “spiral” 456 or “spiral electrode”, which optionally includes more than one electrode (e.g. exposed conductors or an electrode array disposed thereon). [0115] While three configurations have been disclosed (i.e., a basket, an umbrella, and a spiral electrode), these are for illustration purposes only as other deployable electrode configurations dimensioned to fit the desired location (e.g., azygos vein or SVC near the cardiac branch) are also possible. [0116] Details of alternative “self-orienting” electrodes, are shown in FIGS. 16-19, that is, electrode configurations that would concentrate the current density in a direction towards the tissue adjoining the vagal and cardiac branch nerves. [0117] FIGS. 16-17 show, in plan and axial cross-sectional views, an electrode portion 710 of a lead including an insulating tubing 720 includes three electrodes 712, 714, 716. According to an exemplary lead, the electrodes 712, 714, 716 have a fixed or fixable orientation with respect to the lead. The fixed or fixable orientation allows for electrode orientation prior to positioning of the lead in a patient's body or vein. Thus, according to this exemplary lead, the need to selectively employ electrodes to direct pulses applied to the electrodes to the desired nerve fibers or nerve regions is eliminated. As shown in FIG. 17, according to the exemplary fixed or fixable orientation lead, an electrode portion having, or using, only one or two of the three electrodes 712, 714, 716, allows for adequate vagal stimulation. [0118] The same reasoning applies to the electrode portion 760 shown in FIGS. 18-19, which show, in plan and axial cross-sectional views, an electrode portion 760 of a lead including an insulating tubing 770 includes three electrodes 762, 764, 766. [0119] A fixed or fixable lead and/or electrode portion orientation is achieved in a variety of manners. For example, consider a lead fixed or fixable for positioning in a patient's azygos vein 170. For example, the electrode portion 760 in shown in FIG. 20, and is placed in the azygos vein. [0120] [0120]FIG. 20 illustrates a single-pass lead 360 that combines the functions of the any desired connection (e.g., 104, 106 or 108) and with an “side arm” vagal connection 110. As shown in this embodiment, the vagal electrode is the electrode portion 760 shown in FIG. 18, but one of skill in the art could readily substitute the electrode portion 710 shown in FIG. 16. Accordingly, it can be appreciated that the electrodes can be oriented towards the tissue proximate to the vagal and cardiac branch nerves. [0121] Thus, according to this example, the lead turns from the superior vena cava 160 to the azygos vein 170. The part of the lead that “turns” or extends into the azygos vein 160 allows for a fixed or fixable orientation. [0122] The leads shown in FIGS. 7, 9 and 10 demonstrate other fixed or fixable orientation concept, referred to herein as a “side arm” as opposed to the aforementioned “turn”. That is, the leads have fixed orientations due to at least one side arm. The side arm vagal portions dictate the orientation of their respective vagal portions in relation to the azygos vein. Thus, these side arm vagal portions also orient the vagal electrode portions in relation to the right vagus nerve and/or cardiac branch thereof. [0123] For both the turn and side arm leads, the relatively short distance between (or including) the arch of the azygos vein 170 and the superior vena cava 160 allows for leads having an equally short vagal portion that is not particularly susceptible to twisting or misorientation. In other words, a turn lead having a vagal portion that is amenable to unpredictable twisting does not guarantee any reliable degree of orientation of a vagal portion electrode. Under such circumstances, an increase in vagal portion length generally increases the risk of misorientation. Thus, in general, a turn lead aids mainly in depth positioning and not necessarily in rotational positioning between the lead (e.g., vagal portion) and the walls of the vein. In this regard, a side arm lead can exhibit significant advantages over a turn lead. [0124] Referring to FIG. 20, the vagal portion 760 includes electrode portions such as those shown in FIG. 19. According to this example, the side arm orients the electrode portion(s), preferably to alleviate the need to selectively employ electrodes to direct pulses applied to the electrodes to the desired nerve fibers or nerve regions. For example, referring to FIG. 17, the position of electrodes 712, 714, and 716 with respect to the azygos vein and right vagus nerve is generally known. With such information, a device may be configured to use only the electrodes facing the vagus nerve. Referring to FIG. 19, the orientation of electrodes 762, 764, 766 with respect to the azygos vein and right vagus nerve is known a priori. In addition, such an electrode portion may include taper or an “S” wiggle, wherein two electrodes 762, 766 are located on one side of the “S” and one electrode 764 is located on the other side of the “S”. The a priori orientation information allows a device to be preprogrammed or wired to use only the electrodes can expect to achieve the most desirable pattern of nerve stimulation. [0125] In yet another exemplary lead, an electrode portion optionally includes hooks, tines, and/or wiggles to orient and/or secure the vagal portion. Again, the use of hooks, tines, wiggles, and/or equivalents thereof alleviates the need to selectively employ electrodes to direct pulses applied to the electrodes to the desired nerve fibers or nerve regions. [0126] FIGS. 5-10 and FIG. 20 show leads having a deployed electrode portion proximate to a distal portion positioned in a patient's superior vena cava 160. The position of the electrode portion in the superior vena cava 160 is proximate to the patient's right vagus nerve 180 and/or the cardiac branch 184 of the right vagus nerve 180. In these embodiment, the electrode portion appears in one of a location above the azygos vein 170, or in the superior vena cava 160 near the vagal nerves. Through such positioning, the electrode portion may stimulate the right vagus nerve 180, the cardiac branch 184 of the right vagus nerve 180, and/or a combination of both. [0127] In any of the embodiment thus far described, the electrodes are implanted transvenously, in a undeployed state into a region proximate to the vagal nerves, and then deployed using conventional stylet, pull-wire, or guiding sheath. The lead may further contain, in a single-pass configuration, other electrodes for sensing and/or pacing and/or shock therapy to other chambers of the heart, as needed or desired. [0128] Methods for Vagal Stimulation [0129] The leads presented herein and equivalents thereof are suitable for stimulating a patient's vagus nerve. In an exemplary method, the method applies vagal stimulation of varying intensities until a desired reduced heart rate is achieved. In another embodiment, the method includes steps for automatically determining a parameter combination that defines the intensity (i.e., amplitude, pulse width and frequency) that achieves a desired reduced heart rate. In a further embodiment, the A-V conduction is monitored to ensure that A-V dissociation does not occur from too high an intensity of vagal stimulation. [0130] And in still another embodiment, the power consumption is monitored and a plurality of parameter combinations that defines the intensity are tested to determine preferred combinations that do not draw too much current drain. Such a method optionally adjusts one or more of frequency, pulse width and/or amplitude of the stimulating. Such adjusting optionally occurs periodically during treatment of tachycardia and/or as part of a pre-treatment calibration sequence. [0131] Advantageously, such methods of vagal stimulation will have a slowing effect on rate of sinus node depolarization and possible AV nodal conduction velocity which will aid in the control of heart rhythms and/or to aid in remodeling of the heart. In particular, control of the vagal tone can enhance tachycardia therapy. [0132] An exemplary method responds to fast atrial rhythms such as pathological sinus tachycardia, atrial flutter, and atrial fibrillation by stimulating the right vagus nerve to slow a patient's heart sinus rhythm without causing A-V dissociation. [0133] In any of the embodiments described below, upon detection of a high atrial rate, the system will deliver vagal stimulation through the deployed electrode to the vagal nerves by way of the right azygos vein. The system then check for an appropriate rate decrease, and further optimizes the appropriate stimulation level and further checks to see when the vagal stimulation is no longer needed. An exemplary method includes positioning an electrode portion of a lead in a patient's azygos vein and delivering an electrical signal to the electrode portion. In this exemplary method, the delivering optionally includes periodic delivery of an electrical signal having a desired magnitude. While fixed values may be programmed into the device based on implant testing, the present invention contemplates automatically determining an appropriate level of vagal stimulation by determining a level of amplitude, pulse width and frequency that are most effective in attaining the desired heart rate, and preferably can also optimize the current drain by determining the most efficient combination of amplitude, pulse width and frequency that attains the desired heart rate, as will be described below in conjunction with FIGS. 21-24. [0134] [0134]FIG. 21 shows a step diagram of an exemplary method 1500. A positioning step 1504 includes positioning of an electrode portion of a vagal lead in an appropriate vessel, such as, but not limited to, the azygos vein. An adjusting step 1506 adjusts vagal stimulation parameters (i.e., amplitude, pulse width and frequency), either manually or as described in more detail in FIG. 23. A sensing step 1508 senses cardiac activity, such as atrial heart rate. Next, a determination step 1512 determines whether the sensed cardiac activity is within desired limits. If yes at step 1512, then the method will disable vagal stimulation if it is currently turned on (at step 1514), and then returns to the sense step 1508 which continues senses cardiac activity. Thus, the sensing of heart rate within a normal range is determined by the determination step 1512 periodically (or continuously). [0135] If the sensed cardiac activity is not within the limits at step 1512, then a stimulation step 1516 causes stimulation of the vagus nerve. A determination step 1520 follows to determine if the vagal nerve stimulation causes an appropriate decrease in heart rate, e.g., a rate decrease by approximate � the previous rate or simply a rate decrease in the normal range. If a decrease in heart rate is detected in step 1520, then the method returns to the sensing step 1508. [0136] If, on the other hand, a decrease in heart rate is not detected in step 1520, then an adjusting step 1524 further adjusts the vagal stimulation parameters and returns to the stimulation step 1516 and the determination step 1520. This process continues until a desired set of vagal stimulation parameters is found to achieve the desired heart rate. [0137] Once the desired heart rate is achieved (yes, at the determination step 1520), then vagal stimulation will continue for a desired time period (step 1528) (other pacing and/or monitoring functions being performed in the background as needed) until it is time to test to see if the underlying rhythm has returned to normal (steps 1508 and 1512) and, if so, then vagal stimulation can be turned off at step 1514. Thus, vagal stimulation is provided “on demand”, that is, only when needed. [0138] [0138]FIG. 22 illustrates several different responses to vagal stimulation. The upper plot shows cardiac activity with respect to time on a ECG strip while the lower plot shows vagal stimulation with respect to time. In both the upper and lower plots, three different segments, labeled I, II, and III, are shown. Rate I corresponds to tachycardia and vagal stimulation at a level that is insufficient to slow the rate. Rate II corresponds to a level of vagal stimulation that is sufficient to slow heart rate and eliminate tachycardia; thus, Rate II is less than Rate I. In the third segment, the level of vagal stimulation induces A-V dissociation which is observed on the ECG as being treated with backup ventricular pacing. For optimal results, vagal stimulation parameters should be adjustable to permit operation as shown in segment 11. [0139] [0139]FIG. 23 shows an exemplary method 1501 for adjusting vagal stimulation parameters to prevent A-V dissociation. The method proceeds with the same method as described above in FIG. 21 (like numbers being used throughout) until the determination step 1520. [0140] As described with reference to FIG. 22, a given parameter combination that defines the intensity of the vagal stimulation may produce: (I) no decrease in heart rate; (II) a decrease in heart rate; or (III) A-V dissociation. If a decrease in heart rate has not occurred at step 1520, then further adjustment (e.g., increase) of a parameter or parameters is warranted, at the adjusting step 1524. [0141] If the determination step 1520 detects a decrease in heart rate, then the method, at step 1526, determines whether A-V dissociation has occurred. If A-V dissociation has occurred, then further adjustment (e.g., a decrease) of a parameter or parameters is warranted, i.e., back to a level that did not cause A-V dissociation, at the adjusting step 1524. If AV dissociation has not occurred at step 1526, then the method continues as described above to continue providing vagal stimulation only when needed (i.e., on demand) and at a level that does not incur A-V dissociation. [0142] [0142]FIG. 24 shows an exemplary subroutine for step 1524 for adjusting vagal stimulation parameters to prevent A-V dissociation and further for determining a set of parameters that reduces, or minimizes, current drain. In the adjusting step 1524, a user and/or device adjusts a desired vagal stimulation parameter or parameters; such parameters include, but are not limited to, frequency, amplitude and pulse width. [0143] The method begins at step 1550 with an initialization step, in which two parameters (e.g., frequency of stimulation and pulse width) may be set to a fixed values and a third parameter (hereinafter the “parameter under test”, e.g., the amplitude) is initialized to a low value. [0144] In step 1552, the value of the parameter under test (e.g., the amplitude) is then increased until a decrease in heart rate is detected in step 1554. If there has not been a heart rate decrease, then the parameter under test is further increased in step 1552. [0145] If there has been a heart rate decrease at step 1554, then this is the lowest value for the parameter under test when used in combination with the fixed parameters. The method then may (optionally) proceed to step 1558 to further characterize the same parameter under test at higher values to determine if additional changes in rate can be obtained. Thus, a determination is made at step 1558 to verify that A-V dissociation has not occurred, and if not, then a recording step 1560 may record parameter values corresponding to the attained heart rate decrease, and/or power demand associated with vagal stimulation for the parameters. [0146] The method may end here or, optionally, may continue to characterize the other two parameters (e.g., frequency or pulse width) in step 1564. The device may terminate the characterization once several combinations are found and it is apparent that at least one combination that achieves the desired heart rate and reduces current drain has been found. [0147] Again, this particular method 1524 aims to adjust vagal stimulation parameters to decrease heart rate without causing A-V dissociation. The device can then operate using the set of parameters that reduces or minimizes current drain, thereby prolonging batter life. [0148] The device 100 described with reference to FIG. 2 optionally implements aforementioned methods and leads. In particular, device 100 includes a vagal module 238 capable of performing a variety of tasks related to vagal stimulation. [0149] As described herein an exemplary implantable stimulation lead has an electrode portion capable of stimulation of the right vagus nerve with leads to the heart for stimulating parasympathetic nerves for decreasing atrial heart rate (and preferably, without stimulating the phrenic nerve which can evoke undesirable diaphragmatic stimulation). One particular location of stimulation includes the cardiac branch site where the right vagus nerve enters into the right atrium at the level of the SVC/RA junction, or just below the azygos vein. [0150] Other exemplary methods, described herein, include adjusting vagal stimulation until a desired reduction in atrial heart rate is achieved, while preserving sinus rhythm and A-V synchrony. In the event that provides backup A-V sequential support pacing is needed, the methods herein can be configured to do so in the event that asystole or A-V dissociation occurs. [0151] One particular exemplary single-pass implantable stimulation lead can stimulate a desired portion of the right vagus nerve and stimulate the right atrium, the right ventricle and/or the left ventricle. Such leads optionally include an orientation which is generally known with reference to a patient's azygos vein, azygos arch, and/or hemiazygos veins. [0152] Although the invention has been described in language specific to structural features and/or methodological acts, it is to be understood that the subject matter defined in the appended claims is not necessarily limited to the specific features or acts described. Rather, the specific features and acts are disclosed as exemplary forms of implementing the claimed invention. Citas de patentes Patente citada Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS6697677 *5 Abr 200124 Feb 2004Medtronic, Inc.System and method for placing a medical electrical lead* Citada por examinador Citada por Patente citante Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS6738666 *1 Nov 200118 May 2004Pacesetter, Inc.Detection of orthostatic hypotension using positional data and cross-check dataUS7123961 *7 May 200417 Oct 2006Pacesetter, Inc.Stimulation of autonomic nervesUS71943138 Jun 200420 Mar 2007Cardiac Pacemakers, Inc.Baroreflex therapy for disordered breathingUS7245967 *11 Jun 200317 Jul 2007Pacesetter, Inc.Parasympathetic nerve stimulation for termination of supraventricular arrhythmiasUS726043120 May 200421 Ago 2007Cardiac Pacemakers, Inc.Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac deviceUS7305265 *24 Nov 20034 Dic 2007Terumo Kabushiki KaishaHeart treatment equipment for treating heart failureUS7321793 *13 Jun 200322 Ene 2008Biocontrol Medical Ltd.Vagal stimulation for atrial fibrillation therapyUS740381911 Jun 200322 Jul 2008Pacesetter, Inc.Parasympathetic nerve stimulation for control of AV conductionUS746090624 Dic 20032 Dic 2008Cardiac Pacemakers, Inc.Baroreflex stimulation to treat acute myocardial infarctionUS748699124 Dic 20033 Feb 2009Cardiac Pacemakers, Inc.Baroreflex modulation to gradually decrease blood pressureUS749316110 May 200517 Feb 2009Cardiac Pacemakers, Inc.System and method to deliver therapy in presence of another therapyUS750916624 Dic 200324 Mar 2009Cardiac Pacemakers, Inc.Automatic baroreflex modulation responsive to adverse eventUS75428005 Abr 20052 Jun 2009Cardiac Pacemakers, Inc.Method and apparatus for synchronizing neural stimulation to cardiac cyclesUS7561918 *14 Jul 2009Cyberonics, Inc.Autocapture in a neurostimulatorUS757099920 Dic 20054 Ago 2009Cardiac Pacemakers, Inc.Implantable device for treating epilepsy and cardiac rhythm disordersUS758723811 Mar 20058 Sep 2009Cardiac Pacemakers, Inc.Combined neural stimulation and cardiac resynchronization therapyUS761699010 Nov 2009Cardiac Pacemakers, Inc.Implantable and rechargeable neural stimulatorUS764387524 Dic 20035 Ene 2010Cardiac Pacemakers, Inc.Baroreflex stimulation system to reduce hypertensionUS764711412 Ene 2010Cardiac Pacemakers, Inc.Baroreflex modulation based on monitored cardiovascular parameterUS76573123 Nov 20032 Feb 2010Cardiac Pacemakers, Inc.Multi-site ventricular pacing therapy with parasympathetic stimulationUS76606289 Feb 2010Cardiac Pacemakers, Inc.System to provide myocardial and neural stimulationUS76762752 May 20059 Mar 2010Pacesetter, Inc.Endovascular lead for chronic nerve stimulationUS770501612 Feb 200427 Abr 2010Albert Einstein College Of Medicine Of Yeshiva UniversityRegulation of food intake by modulation of long-chain fatty acyl-CoA levels in the hypothalamusUS770688424 Dic 200327 Abr 2010Cardiac Pacemakers, Inc.Baroreflex stimulation synchronized to circadian rhythmUS771591522 Dic 200611 May 2010Pacesetter, Inc.Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for prevention of atrial tachyarrhythmiasUS7734341 *6 Jun 20068 Jun 2010Cardiac Pacemakers, Inc.Method and apparatus for gastrointestinal stimulation via the lymphatic systemUS7734348 *10 May 20058 Jun 2010Cardiac Pacemakers, Inc.System with left/right pulmonary artery electrodesUS774732329 Jun 2010Cardiac Pacemakers, Inc.Adaptive baroreflex stimulation therapy for disordered breathingUS7765000 *10 May 200527 Jul 2010Cardiac Pacemakers, Inc.Neural stimulation system with pulmonary artery leadUS777871117 Ago 2010Bio Control Medical (B.C.M.) Ltd.Reduction of heart rate variability by parasympathetic stimulationUS77833539 Nov 200624 Ago 2010Cardiac Pacemakers, Inc.Automatic neural stimulation modulation based on activity and circadian rhythmUS778336622 Feb 200724 Ago 2010Pacesetter, Inc.Lead for AV nodal vagal stimulation through an epicardial fat padUS780519313 Jul 200728 Sep 2010Cardiac Pacemakers, Inc.Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac deviceUS781380511 Ene 200612 Oct 2010Pacesetter, Inc.Subcardiac threshold vagal nerve stimulationUS781381212 Oct 2010Cvrx, Inc.Baroreflex stimulator with integrated pressure sensorUS782689922 Dic 20062 Nov 2010Pacesetter, Inc.Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for termination of atrial tachyarrhythmiasUS783316416 Nov 2010Cardiac Pacemakers, Inc.System and method for monitoring autonomic balance and physical activityUS784026623 Nov 2010Cardiac Pacemakers, Inc.Integrated lead for applying cardiac resynchronization therapy and neural stimulation therapyUS784027120 Jul 200523 Nov 2010Cvrx, Inc.Stimulus regimens for cardiovascular reflex controlUS78443462 Feb 200630 Nov 2010Biocontrol Medical Ltd.Electrode assembly for nerve controlUS786986911 Ene 2011Pacesetter, Inc.Subcardiac threshold vagal nerve stimulationUS786988124 Dic 200311 Ene 2011Cardiac Pacemakers, Inc.Baroreflex stimulator with integrated pressure sensorUS787341318 Ene 2011Cardiac Pacemakers, Inc.Closed loop neural stimulation synchronized to cardiac cyclesUS788178220 Abr 20051 Feb 2011Cardiac Pacemakers, Inc.Neural stimulation system to prevent simultaneous energy dischargesUS78857098 Feb 2011Bio Control Medical (B.C.M.) Ltd.Nerve stimulation for treating disordersUS788571110 Jun 20048 Feb 2011Bio Control Medical (B.C.M.) Ltd.Vagal stimulation for anti-embolic therapyUS78949066 Jun 200622 Feb 2011Cardiac Pacemakers, Inc.Amelioration of chronic pain by endolymphatic stimulationUS79041767 Sep 20068 Mar 2011Bio Control Medical (B.C.M.) Ltd.Techniques for reducing pain associated with nerve stimulationUS791723029 Mar 2011Cardiac Pacemakers, Inc.Neurostimulating lead having a stent-like anchorUS794940024 May 2011Cvrx, Inc.Devices and methods for cardiovascular reflex control via coupled electrodesUS794940924 May 2011Cardiac Pacemakers, Inc.Dual spiral lead configurationsUS79746935 Jul 2011Bio Control Medical (B.C.M.) Ltd.Techniques for applying, configuring, and coordinating nerve fiber stimulationUS797914112 Jul 2011Cardiac Pacemakers, Inc.Transvascular reshaping lead systemUS79837519 Ago 200619 Jul 2011Proteus Biomedical, Inc.Measuring conduction velocity using one or more satellite devicesUS800079323 May 200816 Ago 2011Cardiac Pacemakers, Inc.Automatic baroreflex modulation based on cardiac activityUS800255323 Ago 2011Cardiac Pacemakers, Inc.Sleep quality data collection and evaluationUS801944313 Sep 2011Boston Scientific Neuromodulation CorporationAnchoring units for leads of implantable electric stimulation systems and methods of making and usingUS802405020 Sep 2011Cardiac Pacemakers, Inc.Lead for stimulating the baroreceptors in the pulmonary arteryUS803674331 Mar 200611 Oct 2011Proteus Biomedical, Inc.Automated optimization of multi-electrode pacing for cardiac resynchronizationUS806020615 Nov 2011Cvrx, Inc.Baroreflex modulation to gradually decrease blood pressureUS806500327 May 200822 Nov 2011Cardiac Pacemakers, Inc.Demand-based cardiac function therapyUS808631427 Dic 2011Cvrx, Inc.Devices and methods for cardiovascular reflex controlUS812169323 Oct 200821 Feb 2012Cardiac Pacemakers, Inc.Baroreflex stimulation to treat acute myocardial infarctionUS81265386 Jun 200628 Feb 2012Cardiac Pacemakers, Inc.Method and apparatus for introducing endolymphatic instrumentationUS812655930 Nov 200428 Feb 2012Cardiac Pacemakers, Inc.Neural stimulation with avoidance of inappropriate stimulationUS812656024 Dic 200328 Feb 2012Cardiac Pacemakers, Inc.Stimulation lead for stimulating the baroreceptors in the pulmonary arteryUS81265615 Nov 200928 Feb 2012Cardiac Pacemakers, Inc.Implantable and rechargeable neural stimulatorUS813135923 Abr 20086 Mar 2012Cardiac Pacemakers, Inc.System and method to deliver therapy in presence of another therapyUS813136219 Ago 20096 Mar 2012Cardiac Pacemakers, Inc.Combined neural stimulation and cardiac resynchronization therapyUS813137330 Mar 20106 Mar 2012Cardiac Pacemakers, Inc.Baroreflex stimulation synchronized to circadian rhythmUS813546430 Jul 200713 Mar 2012Pacesetter, Inc.Painless ventricular rate control during supraventricular tachycardiaUS817066814 Jul 20061 May 2012Cardiac Pacemakers, Inc.Baroreflex sensitivity monitoring and trending for tachyarrhythmia detection and therapyUS817570512 Oct 20048 May 2012Cardiac Pacemakers, Inc.System and method for sustained baroreflex stimulationUS81952895 Jun 2012Cardiac Pacemakers, Inc.Baroreflex stimulation system to reduce hypertensionUS820033112 Jun 2012Cardiac Pacemakers, Inc.System and method for filtering neural stimulationUS820033212 Jun 2012Cardiac Pacemakers, Inc.System and method for filtering neural stimulationUS820459124 Ene 200719 Jun 2012Bio Control Medical (B.C.M.) Ltd.Techniques for prevention of atrial fibrillationUS822443717 Jul 2012Cvrx, Inc.Baroreflex activation for sedation and sleepUS822446017 Jul 2012Boston Scientific Neuromodulation CorporationAnchoring units for leads of implantable electric stimulation systems and methods of making and usingUS823398731 Jul 2012Respicardia, Inc.Respiratory rectificationUS8244377 *27 Sep 200714 Ago 2012Boston Scientific Neuromodulation CorporationFixation arrangements for implantable leads and methods of making and usingUS824437814 Ago 2012Cardiac Pacemakers, Inc.Spiral configurations for intravascular lead stabilityUS82853899 Oct 2012Cardiac Pacemakers, Inc.Automatic neural stimulation modulation based on motion and physiological activityUS829059516 Oct 2012Cvrx, Inc.Method and apparatus for stimulation of baroreceptors in pulmonary arteryUS829594323 Oct 2012Medtronic, Inc.Implantable medical lead with biased electrodeUS831164713 Nov 2012Cardiac Pacemakers, Inc.Direct delivery system for transvascular leadUS832102327 Ene 200927 Nov 2012Cardiac Pacemakers, Inc.Baroreflex modulation to gradually decrease blood pressureUS832641820 Ago 20084 Dic 2012Medtronic, Inc.Evaluating therapeutic stimulation electrode configurations based on physiological responsesUS832643819 Oct 20094 Dic 2012Bio Control Medical (B.C.M.) Ltd.Techniques for nerve stimulationUS833204716 Nov 200511 Dic 2012Cardiac Pacemakers, Inc.System and method for closed-loop neural stimulationUS835578413 May 201115 Ene 2013Medtronic, Inc.Dynamic representation of multipolar leads in a programmer interfaceUS836994322 Oct 20095 Feb 2013Cardiac Pacemakers, Inc.Method and apparatus for neural stimulation via the lymphatic systemUS838605626 Feb 2013Bio Control Medical (B.C.M.) Ltd.Parasympathetic stimulation for treating atrial arrhythmia and heart failureUS839656018 Nov 200412 Mar 2013Cardiac Pacemakers, Inc.System and method for closed-loop neural stimulationUS840687626 Mar 2013Cardiac Pacemakers, Inc.Closed loop neural stimulation synchronized to cardiac cyclesUS841234729 Abr 20092 Abr 2013Proteus Digital Health, Inc.Methods and apparatus for leads for implantable devicesUS84123502 Abr 2013Cardiac Pacemakers, Inc.Neurostimulating lead having a stent-like anchorUS841735413 May 20109 Abr 2013Cardiac Pacemakers, Inc.Methods for using a pulmonary artery electrodeUS8433412 *6 Feb 200930 Abr 2013Respicardia, Inc.Muscle and nerve stimulationUS844263817 May 201014 May 2013Cardiac Pacemakers, Inc.Adaptive baroreflex stimulation therapy for disordered breathingUS84426404 Ene 201014 May 2013Cardiac Pacemakers, Inc.Neural stimulation modulation based on monitored cardiovascular parameterUS844947227 Sep 201028 May 2013Pacesetter, Inc.Neurostimulation and neurosensing techniques to optimize atrial anti-tachycardia pacing for prevention of atrial tachyarrhythmiasUS845239828 May 2013Cardiac Pacemakers, Inc.Method and apparatus for synchronizing neural stimulation to cardiac cyclesUS84577344 Jun 2013Cardiac Pacemakers, Inc.System and method for neural stimulationUS84577464 Ago 20114 Jun 2013Cardiac Pacemakers, Inc.Implantable systems and devices for providing cardiac defibrillation and apnea therapyUS847306927 Feb 200925 Jun 2013Proteus Digital Health, Inc.Integrated circuit implementation and fault control system, device, and methodUS84730766 Sep 201125 Jun 2013Cardiac Pacemakers, Inc.Lead for stimulating the baroreceptors in the pulmonary arteryUS847839713 Ene 20102 Jul 2013Cardiac Pacemakers, Inc.System to provide myocardial and neural stimulationUS847841430 Abr 20082 Jul 2013Cvrx, Inc.Baroreflex activation for pain control, sedation and sleepUS848382312 Oct 20109 Jul 2013Cardiac Pacemakers, Inc.Integrated lead for applying cardiac resynchronization therapy and neural stimulation therapyUS848382827 Sep 20109 Jul 2013Cardiac Pacemakers, Inc.Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac deviceUS848382920 Sep 20129 Jul 2013Medtronic, Inc.Dynamic representation of multipolar leads in a programmer interfaceUS849465512 Oct 201123 Jul 2013Bio Control Medical (B.C.M.) Ltd.Electrode devices with resistive elementsUS84987213 Oct 201130 Jul 2013Cardiac Pacemakers, Inc.Coronary vein leads having pre-formed biased portions for fixationUS850414915 Feb 20126 Ago 2013Cardiac Pacemakers, Inc.System and method to deliver therapy in presence of another therapyUS850991729 Jun 201213 Ago 2013Boston Scientific Neuromodulation CorporationAnchoring units for leads of implantable electric stimulation systems and methods of making and usingUS85270643 Dic 20083 Sep 2013Cardiac Pacemakers, Inc.System for stimulating autonomic targets from pulmonary arteryUS853852314 Sep 201217 Sep 2013Medtronic, Inc.Evaluating therapeutic stimulation electrode configurations based on physiological responsesUS85412328 Mar 200724 Sep 2013Kwalata Trading LimitedComposition comprising a progenitor/precursor cell populationUS85485857 Dic 20101 Oct 2013Cardiac Pacemakers, Inc.Concurrent therapy detection in implantable medical devicesUS85600765 Nov 201015 Oct 2013Cvrx, Inc.Devices and methods for electrode implantationUS85716517 Feb 201129 Oct 2013Bio Control Medical (B.C.M.) Ltd.Techniques for reducing pain associated with nerve stimulationUS85716537 Feb 201129 Oct 2013Bio Control Medical (B.C.M.) Ltd.Nerve stimulation techniquesUS857165526 Ene 201029 Oct 2013Cardiac Pacemakers, Inc.Multi-site ventricular pacing therapy with parasympathetic stimulationUS85832368 Mar 201012 Nov 2013Cvrx, Inc.Devices and methods for cardiovascular reflex controlUS860635913 Abr 200710 Dic 2013Cvrx, Inc.System and method for sustained baroreflex stimulationUS860908225 Ene 200617 Dic 2013Bio Control Medical Ltd.Administering bone marrow progenitor cells or myoblasts followed by application of an electrical current for cardiac repair, increasing blood supply or enhancing angiogenesisUS862628215 Nov 20127 Ene 2014Cardiac Pacemakers, Inc.Baroreflex modulation to gradually change a physiological parameterUS86263013 Jun 20137 Ene 2014Cardiac Pacemakers, Inc.Automatic baroreflex modulation based on cardiac activityUS863071922 Oct 201214 Ene 2014Medtronic, Inc.Implantable medical lead with biased electrodeUS863492122 Feb 201221 Ene 2014Cardiac Pacemakers, Inc.Implantable and rechargeable neural stimulatorUS863932230 May 201228 Ene 2014Cardiac Pacemakers, Inc.System and method for delivering myocardial and autonomic neural stimulationUS8660647 *28 Jul 200525 Feb 2014Cyberonics, Inc.Stimulating cranial nerve to treat pulmonary disorderUS866064815 Nov 201225 Feb 2014Cardiac Pacemakers, Inc.Implantable and rechargeable neural stimulatorUS868243414 Feb 201225 Mar 2014Cardiac Pacemakers, Inc.Neural stimulation with avoidance of inappropriate stimulationUS86857241 Jun 20051 Abr 2014Kwalata Trading LimitedIn vitro techniques for use with stem cellsUS871253124 May 201229 Abr 2014Cvrx, Inc.Automatic baroreflex modulation responsive to adverse eventUS871254911 Dic 200329 Abr 2014Proteus Digital Health, Inc.Method and system for monitoring and treating hemodynamic parametersUS871877021 Oct 20106 May 2014Medtronic, Inc.Capture threshold measurement for selection of pacing vectorUS871878919 Abr 20106 May 2014Cvrx, Inc.Electrode structures and methods for their use in cardiovascular reflex controlUS872527111 Jul 201313 May 2014Bio Control Medical (B.C.M.) Ltd.Electrode device with elongated electrodeUS8731659 *20 Sep 200520 May 2014Cardiac Pacemakers, Inc.Multi-site lead/system using a multi-pole connection and methods thereforUS875101612 Ago 201310 Jun 2014Boston Scientific Neuromodulation CorporationAnchoring units for leads of implantable electric stimulation systems and methods of making and usingUS875590721 May 201317 Jun 2014Cvrx, Inc.Devices and methods for electrode implantationUS876846230 May 20121 Jul 2014Cardiac Pacemakers, Inc.System and method for filtering neural stimulationUS878604923 Jul 201022 Jul 2014Proteus Digital Health, Inc.Solid-state thin-film capacitorUS880549430 Jul 201312 Ago 2014Cardiac Pacemakers, Inc.System and method to deliver therapy in presence of another therapyUS880550125 Ene 201212 Ago 2014Cardiac Pacemakers, Inc.Baroreflex stimulation to treat acute myocardial infarctionUS880551323 Abr 201312 Ago 2014Cardiac Pacemakers, Inc.Neural stimulation modulation based on monitored cardiovascular parameterUS88185131 Mar 201226 Ago 2014Cardiac Pacemakers, Inc.Baroreflex stimulation synchronized to circadian rhythmUS883171817 Ene 20119 Sep 2014Cardiac Pacemakers, Inc.Neural stimulation system to prevent simultaneous energy dischargesUS88382398 Jul 201316 Sep 2014Cardiac Pacemakers, Inc.Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac deviceUS883824627 Sep 200616 Sep 2014Cvrx, Inc.Devices and methods for cardiovascular reflex treatmentsUS887421115 Dic 201028 Oct 2014Cardiac Pacemakers, Inc.Hypertension therapy based on activity and circadian rhythmUS888019030 Nov 20124 Nov 2014Cvrx, Inc.Electrode structures and methods for their use in cardiovascular reflex controlUS88801922 Abr 20124 Nov 2014Bio Control Medical (B.C.M.) Ltd.Electrode cuffsUS88978786 May 201025 Nov 2014Cardiac Pacemakers, Inc.Method and apparatus for gastrointestinal stimulation via the lymphatic systemUS89059991 Sep 20069 Dic 2014Cardiac Pacemakers, Inc.Method and apparatus for endolymphatic drug deliveryUS8909341 *18 Ene 20089 Dic 2014Respicardia, Inc.Device and method for the treatment of breathing disorders and cardiac disordersUS890935526 Oct 20129 Dic 2014Bio Control Medical (B.C.M.) Ltd.Techniques for nerve stimulationUS891574123 Ago 201123 Dic 2014Cardiac Pacemakers, Inc.Sleep quality data collection and evaluationUS892999015 Dic 20106 Ene 2015Cardiac Pacemakers, Inc.Transvascular neural stimulation device and method for treating hypertensionUS89835984 Oct 200617 Mar 2015Cardiac Pacemakers, Inc.System for neurally-mediated anti-arrhythmic therapyUS90024483 Jun 20137 Abr 2015Cardiac Pacemakers, Inc.System and method for neural stimulationUS902059519 May 201028 Abr 2015Cardiac Pacemakers, Inc.Baroreflex activation therapy with conditional shut offUS90316507 Ene 201112 May 2015Cardiac Pacemakers, Inc.Closed loop neural stimulation synchronized to cardiac cyclesUS903166912 Ago 201312 May 2015Cardiac Pacemakers, Inc.System for transvascularly stimulating autonomic targetsUS904460918 Nov 20112 Jun 2015Cvrx, Inc.Electrode structures and methods for their use in cardiovascular reflex controlUS9084898 *8 Ago 201221 Jul 2015Cardiac Pacemakers, Inc.Method and device for providing anti-tachyarrhythmia therapyUS9149639 *2 Abr 20136 Oct 2015Cardiac Pacemakers, Inc.Systems for using a pulmonary artery electrodeUS921141213 Mar 201315 Dic 2015Cardiac Pacemakers, Inc.Closed loop neural stimulation synchronized to cardiac cyclesUS921656312 Ago 201422 Dic 2015Boston Scientific Neuromodulation CorporationLead anchor with adhesive and systems and methods using the lead anchorUS922706829 Ago 20135 Ene 2016Cardiac Pacemakers, Inc.Concurrent therapy detection in implantable medical devicesUS923417320 Ago 201312 Ene 2016Kwalata Trading Ltd.Regulating stem cellsUS926594814 Oct 201423 Feb 2016Cardiac Pacemakers, Inc.Automatic neural stimulation modulation based on activityUS929584627 Mar 201329 Mar 2016Respicardia, Inc.Muscle and nerve stimulationUS931463510 Feb 200919 Abr 2016Cardiac Pacemakers, Inc.Automatic baroreflex modulation responsive to adverse eventUS93208911 Abr 200926 Abr 2016Boston Scientific Neuromodulation CorporationLead anchor for implantable devices and methods of manufacture and useUS20040172074 *24 Nov 20032 Sep 2004Terumo Kabushiki KaishaHeart treatment equipment for treating heart failureUS20040193021 *11 Dic 200330 Sep 2004Proteus Biomedical, Inc., A Delaware CorporationMethod and system for monitoring and treating hemodynamic parametersUS20040193231 *20 Nov 200330 Sep 2004Biocontrol Medical Ltd.Selective nerve fiber stimulation for treating heart conditionsUS20040230241 *12 May 200318 Nov 2004Carlson Gerrard M.Statistical method for assessing autonomic balanceUS20040254612 *13 Jun 200316 Dic 2004Ezra Omry BenVagal stimulation for anti-embolic therapyUS20050065553 *10 Jun 200424 Mar 2005Omry Ben EzraApplications of vagal stimulationUS20050065554 *23 Sep 200324 Mar 2005Kenknight Bruce H.Demand-based cardiac function therapyUS20050090719 *28 Oct 200328 Abr 2005Avram ScheinerSystem and method for monitoring autonomic balance and physical activityUS20050143779 *13 Sep 200430 Jun 2005Cardiac Pacemakers, Inc.Baroreflex modulation based on monitored cardiovascular parameterUS20050143785 *8 Jun 200430 Jun 2005Imad LibbusBaroreflex therapy for disordered breathingUS20050149126 *24 Dic 20037 Jul 2005Imad LibbusBaroreflex stimulation to treat acute myocardial infarctionUS20050149127 *24 Dic 20037 Jul 2005Imad LibbusAutomatic baroreflex modulation responsive to adverse eventUS20050149128 *24 Dic 20037 Jul 2005Heil Ronald W.Jr.Barorflex stimulation system to reduce hypertensionUS20050149129 *24 Dic 20037 Jul 2005Imad LibbusBaropacing and cardiac pacing to control outputUS20050149130 *24 Dic 20037 Jul 2005Imad LibbusBaroreflex stimulation synchronized to circadian rhythmUS20050149131 *24 Dic 20037 Jul 2005Imad LibbusBaroreflex modulation to gradually decrease blood pressureUS20050149132 *24 Dic 20037 Jul 2005Imad LibbusAutomatic baroreflex modulation based on cardiac activityUS20050149133 *24 Dic 20037 Jul 2005Imad LibbusSensing with compensation for neural stimulatorUS20050149143 *24 Dic 20037 Jul 2005Imad LibbusBaroreflex stimulator with integrated pressure sensorUS20050149155 *24 Dic 20037 Jul 2005Avram ScheinerStimulation lead for stimulating the baroreceptors in the pulmonary arteryUS20050149156 *24 Dic 20037 Jul 2005Imad LibbusLead for stimulating the baroreceptors in the pulmonary arteryUS20050187586 *24 Feb 200525 Ago 2005Biocontrol Medical Ltd.Selective nerve fiber stimulation for treating heart conditionsUS20050197675 *18 Feb 20058 Sep 2005Biocontrol Medical Ltd.Techniques for applying, calibrating, and controlling nerve fiber stimulationUS20050251212 *20 Jul 200510 Nov 2005Cvrx, Inc.Stimulus regimens for cardiovascular reflex controlUS20050261741 *20 May 200424 Nov 2005Imad LibbusCombined remodeling control therapy and anti-remodeling therapy by implantable cardiac deviceUS20050288728 *8 Jun 200429 Dic 2005Imad LibbusAdaptive baroreflex stimulation therapy for disordered breathingUS20060025828 *28 Jul 20042 Feb 2006Armstrong Randolph KImpedance measurement for an implantable deviceUS20060079945 *12 Oct 200413 Abr 2006Cardiac Pacemakers, Inc.System and method for sustained baroreflex stimulationUS20060095080 *4 Nov 20044 May 2006Cardiac Pacemakers, Inc.System and method for filtering neural stimulationUS20060100668 *22 Sep 200511 May 2006Biocontrol Medical Ltd.Selective nerve fiber stimulationUS20060106429 *18 Nov 200418 May 2006Cardiac Pacemakers, Inc.System and method for closed-loop neural stimulationUS20060116737 *30 Nov 20041 Jun 2006Cardiac Pacemakers, Inc.Neural stimulation with avoidance of inappropriate stimulationUS20060120971 *6 Oct 20058 Jun 2006Signum Pharmaceuticals, Inc.Agents and methods for administration to the central nervous systemUS20060135998 *16 Nov 200522 Jun 2006Imad LibbusSystem and method for closed-loop neural stimulationUS20060136024 *22 Dic 200422 Jun 2006Biocontrol Medical Ltd.Construction of electrode assembly for nerve controlUS20060161211 *29 Dic 200520 Jul 2006Todd ThompsonImplantable accelerometer-based cardiac wall position detectorUS20060167501 *25 Ene 200627 Jul 2006Tamir Ben-DavidMethod to enhance progenitor or genetically-modified cell therapyUS20060173495 *28 Ene 20053 Ago 2006Cyberonics, Inc.Autocapture in a neurostimulatorUS20060195170 *2 Feb 200631 Ago 2006Ehud CohenElectrode assembly for nerve controlUS20060206153 *11 Mar 200514 Sep 2006Imad LibbusIntegrated lead for applying cardiac resynchronization therapy and neural stimulation therapyUS20060206154 *11 Mar 200514 Sep 2006Julia MoffittCombined neural stimulation and cardiac resynchronization therapyUS20060217772 *23 Mar 200528 Sep 2006Cardiac Pacemakers, Inc.System to provide myocardial and neural stimulationUS20060224188 *5 Abr 20055 Oct 2006Cardiac Pacemakers, Inc.Method and apparatus for synchronizing neural stimulation to cardiac cyclesUS20060241699 *20 Abr 200526 Oct 2006Cardiac Pacemakers, Inc.Neural stimulation system to prevent simultaneous energy dischargesUS20060259083 *10 May 200516 Nov 2006Cardiac Pacemakers, Inc.System and method to deliver therapy in presence of another therapyUS20060259084 *10 May 200516 Nov 2006Cardiac Pacemakers, Inc.System with left/right pulmonary artery electrodesUS20060259085 *10 May 200516 Nov 2006Cardiac Pacemakers, Inc.Neural stimulation system with pulmonary artery leadUS20060271115 *10 Jun 200430 Nov 2006Omry Ben-EzraVagal stimulation for anti-embolic therapyUS20070021790 *7 Jul 200625 Ene 2007Cvrx, Inc.Automatic baroreflex modulation responsive to adverse eventUS20070026079 *13 Feb 20061 Feb 2007Louis HerlandsIntranasal administration of modulators of hypothalamic ATP-sensitive potassium channelsUS20070027496 *28 Jul 20051 Feb 2007Cyberonics, Inc.Stimulating cranial nerve to treat pulmonary disorderUS20070038255 *7 Jul 200615 Feb 2007Cvrx, Inc.Baroreflex stimulator with integrated pressure sensorUS20070066998 *20 Sep 200522 Mar 2007Cardiac Pacemakers, Inc.Multi-site lead/system using a multi-pole connection and methods thereforUS20070093434 *12 Feb 200426 Abr 2007Luciano RossettiRegulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamusUS20070093875 *24 Oct 200526 Abr 2007Cardiac Pacemakers, Inc.Implantable and rechargeable neural stimulatorUS20070106340 *27 Sep 200610 May 2007Cvrx, Inc.Electrode structures and methods for their use in cardiovascular reflex controlUS20070142864 *9 Nov 200621 Jun 2007Imad LibbusAutomatic neural stimulation modulation based on activityUS20070150011 *28 Dic 200528 Jun 2007Meyer Scott ANeural stimulation system for reducing atrial proarrhythmiaUS20070161914 *8 Dic 200612 Jul 2007Mark ZdeblickMethods and systems for measuring cardiac parametersUS20070179543 *24 Ene 20072 Ago 2007Tamir Ben-DavidTechniques for prevention of atrial fibrillationUS20070191904 *14 Feb 200616 Ago 2007Imad LibbusExpandable stimulation electrode with integrated pressure sensor and methods related theretoUS20070282386 *6 Jun 20066 Dic 2007Shuros Allan CMethod and apparatus for gastrointestinal stimulation via the lymphatic systemUS20070282390 *6 Jun 20066 Dic 2007Shuros Allan CAmelioration of chronic pain by endolymphatic stimulationUS20080009719 *6 Jun 200610 Ene 2008Shuros Allan CMethod and apparatus for introducing endolymphatic instrumentationUS20080015659 *25 Sep 200717 Ene 2008Yi ZhangNeurostimulation systems and methods for cardiac conditionsUS20080021504 *24 Jul 200624 Ene 2008Mccabe AaronClosed loop neural stimulation synchronized to cardiac cyclesUS20080021507 *9 Ene 200724 Ene 2008Cardiac Pacemakers, Inc.Sensing with compensation for neural stimulatorUS20080058871 *29 Ago 20066 Mar 2008Imad LibbusSystem and method for neural stimulationUS20080065158 *7 Sep 200613 Mar 2008Omry Ben-EzraTechniques for reducing pain associated with nerve stimulationUS20080086174 *4 Oct 200610 Abr 2008Cardiac Pacemakers, Inc.System for neurally-mediated anti-arrhythmic therapyUS20080091241 *23 Oct 200717 Abr 2008Biocontrol Medical, Ltd.Vagal stimulation for cardioversion of atrial fibrillationUS20080097412 *1 Sep 200624 Abr 2008Shuros Allan CMethod and apparatus for endolymphatic drug deliveryUS20080119898 *25 Oct 200722 May 2008Biocontrol Medical Ltd.Nitric oxide synthase-affecting parasympathetic stimulationUS20080125827 *29 Oct 200729 May 2008Biocontrol Medical Ltd.Selective nerve fiber stimulation for treating heart conditionsUS20080132964 *30 Oct 20075 Jun 2008Biocontrol Medical Ltd.Selective nerve fiber stimulation for treating heart conditionsUS20080177350 *31 Oct 200724 Jul 2008Cvrx, Inc.Expandable Stimulation Electrode with Integrated Pressure Sensor and Methods Related TheretoUS20080183187 *30 Ene 200731 Jul 2008Cardiac Pacemakers, Inc.Direct delivery system for transvascular leadUS20080183253 *30 Ene 200731 Jul 2008Cardiac Pacemakers, Inc.Neurostimulating lead having a stent-like anchorUS20080183254 *30 Ene 200731 Jul 2008Cardiac Pacemakers, Inc.Dual spiral lead configurationsUS20080183255 *30 Ene 200731 Jul 2008Cardiac Pacemakers, Inc.Side port lead delivery systemUS20080183264 *30 Ene 200731 Jul 2008Cardiac Pacemakers, Inc.Electrode configurations for transvascular nerve stimulationUS20080200959 *23 Abr 200821 Ago 2008Cardiac Pacemakers, Inc.System and method to deliver therapy in presence of another therapyUS20080208282 *18 Ene 200828 Ago 2008Mark GelfandDevice and method for the treatment of breathing disorders and cardiac disordersUS20080208286 *30 Abr 200828 Ago 2008Cvrx, Inc.Baroreflex activation for pain control, sedation and sleepUS20080215111 *31 Oct 20074 Sep 2008Cvrx, Inc.Devices and Methods for Cardiovascular Reflex ControlUS20080220466 *1 Jun 200511 Sep 2008Valentin FulgaIn Vitro Techniques For Use With Stem CellsUS20080228238 *23 May 200818 Sep 2008Cardiac Pacemakers, Inc.Automatic baroreflex modulation based on cardiac activityUS20080294218 *31 Mar 200627 Nov 2008Proteus Biomedical, Inc.Automated Optimization of Multi-Electrode Pacing for Cardiac ResynchronizationUS20080294228 *23 May 200727 Nov 2008Cardiac PacemakersMethod and device for controlled stimulation of lymphatic flowUS20080306394 *9 Ago 200611 Dic 2008Zdeblick Mark JMeasuring Conduction Velocity Using One or More Satellite DevicesUS20090030262 *3 Oct 200829 Ene 2009Cvrx, Inc.Baroreflex activation for sedation and sleepUS20090048641 *23 Oct 200819 Feb 2009Cardiac Pacemakers, Inc.Baroreflex stimulation to treat acute myocardial infarctionUS20090054947 *20 Ago 200826 Feb 2009Medtronic, Inc.Electrode configurations for directional leadsUS20090112962 *31 Oct 200730 Abr 2009Research In Motion LimitedModular squaring in binary field arithmeticUS20090143838 *27 Ene 20094 Jun 2009Imad LibbusBaroreflex modulation to gradually decrease blood pressureUS20090149900 *13 Feb 200911 Jun 2009Julia MoffittTransvascular neural stimulation deviceUS20090228059 *27 Abr 200910 Sep 2009Shuros Allan CMethod and device for lymphatic system monitoringUS20090228060 *20 May 200910 Sep 2009Imad LibbusMethod and apparatus for synchronizing neural stimulation to cardiac cyclesUS20090228078 *3 Dic 200810 Sep 2009Yunlong ZhangSystem for stimulating autonomic targets from pulmonary arteryUS20090248095 *27 Mar 20091 Oct 2009Boston Scientific Neuromodulation CorporationAnchoring units for leads of implantable electric stimulation systems and methods of making and usingUS20090254151 *1 Abr 20098 Oct 2009Boston Scientific Neuromodulation CorporationLead anchor for implantable devices and methods of manufacture and useUS20090299447 *30 Jun 20063 Dic 2009Marc JensenDeployable epicardial electrode and sensor arrayUS20090306734 *10 Dic 2009Julia MoffittCombined neural stimulation and cardiac resynchronization therapyUS20100016927 *21 Ene 2010Anthony CaparsoTransvascular reshaping lead systemUS20100042170 *18 Feb 2010Shuros Allan CMethod and apparatus for neural stimulation via the lymphatic systemUS20100042194 *19 Oct 200918 Feb 2010Biocontrol Medical Ltd.Techniques for nerve stimulationUS20100049281 *25 Feb 2010Imad LibbusSystems for providing neural markers for sensed autonomic nervous system activityUS20100114226 *13 Ene 20106 May 2010Imad LibbusSystem to provide myocardial and neural stimulationUS20100114234 *23 Nov 20096 May 2010Proteus Biomedical, Inc.Implantable Satellite EffectorsUS20100121399 *15 Ene 201013 May 2010Mccabe AaronClosed loop neural stimulation synchronized to cardiac cyclesUS20100125307 *26 Ene 201020 May 2010Pastore Joseph MMulti-site ventricular pacing therapy with parasympathetic stimulationUS20100185255 *30 Mar 201022 Jul 2010Imad LibbusBaroreflex stimulation synchronized to circadian rhythmUS20100204766 *22 Dic 200612 Ago 2010Mark ZdeblickImplantable integrated circuitUS20100217346 *6 May 201026 Ago 2010Shuros Allan CMethod and apparatus for gastrointestinal stimulation via the lymphatic systemUS20100222832 *2 Sep 2010Yongxing ZhangMethods for using a pulmonary artery electrodeUS20100249883 *30 Sep 2010Proteus Biomedical, Inc.Methods for Configuring Satellite ElectrodesUS20100274321 *28 Oct 2010Imad LibbusBaroreflex activation therapy with conditional shut offUS20100274336 *27 Abr 200928 Oct 2010Boston Scientific Neuromodulation CorporationTorque lock anchor and methods and devices using the anchorUS20100286741 *11 Nov 2010Imad LibbusCardiac rhythm management device with neural sensorUS20110015690 *27 Sep 201020 Ene 2011Pacesetter, Inc.Neurostimulation and Neurosensing Techniques to Optimize Atrial Anti-Tachycardia Pacing for Prevention of Atrial TachyarrhythmiasUS20110015692 *27 Sep 201020 Ene 2011Imad LibbusCombined remodeling control therapy and anti-remodeling therapy by implantable cardiac deviceUS20110022113 *30 Nov 200927 Ene 2011Mark ZdeblickAnalyzer Compatible Communication ProtocolUS20110034964 *27 Feb 200910 Feb 2011Yafei BiIntegrated Circuit Implementation and Fault Control System, Device, and MethodUS20110040347 *17 Feb 2011Imad LibbusIntegrated lead for applying cardiac resynchronization therapy and neural stimulation therapyUS20110060380 *10 Mar 2011Mark GelfandRespiratory rectificationUS20110082514 *7 Abr 2011Imad LibbusHypertension therapy based on activity and circadian rhythmUS20110082530 *2 Abr 20107 Abr 2011Mark ZdeblickMethod and Apparatus for Implantable LeadUS20110082537 *7 Abr 2011Julia MoffittTransvascular neural stimulation deviceUS20110106199 *7 Ene 20115 May 2011Mccabe AaronClosed loop neural stimulation synchronized to cardiac cyclesUS20110106216 *5 May 2011Imad LibbusBaroreflex stimulator with integrated pressure sensorUS20110112592 *12 May 2011Imad LibbusNeural stimulation system to prevent simultaneous energy dischargesUS20110137374 *5 Nov 20109 Jun 2011Kieval Robert SDevices and methods for electrode implantationUS20110152877 *23 Jun 2011Bly Mark JNeurostimulating lead having a stent-like anchorUS20110178530 *21 Jul 2011Bly Mark JDirect delivery system for transvascular leadUS20110178573 *21 Jul 2011Boston Scientific Neuromodulation CorporationTorque lock anchor and methods and devices using the anchorUS20110224749 *15 Sep 2011Bio Control Medical (B.C.M.) Ltd.Nerve stimulation techniquesUS20120296383 *8 Ago 201222 Nov 2012Dan LiMethod and device for providing anti-tachyarrhythmia therapyUS20130218221 *2 Abr 201322 Ago 2013Cardiac Pacemakers, Inc.Methods for using a pulmonary artery electrodeWO2004110550A2 *10 Jun 200423 Dic 2004Biocontrol Medical Ltd.Vagal stimulation for anti-embolic therapyWO2004110550A3 *10 Jun 200431 Mar 2005David Tamir BenVagal stimulation for anti-embolic therapyWO2008063396A1 *5 Nov 200729 May 2008Cardiac Pacemakers, Inc.Automatic neural stimulation modulation based on activity* Citada por examinadorClasificaciones Clasificaci�n de EE.UU.607/9 Clasificaci�n internacionalA61N1/36, A61N1/05 Clasificaci�n cooperativaA61N1/056, A61N1/36114, A61N2001/0585 Clasificaci�n europeaA61N1/36Z3J, A61N1/05NEventos legales FechaC�digoEventoDescripci�n22 Nov 2001ASAssignmentOwner name: PACESETTER, INC., CALIFORNIAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WEINBERG, LISA P.;LEVINE, PAUL A.;REEL/FRAME:012349/0772Effective date: 2001102223 Feb 2009FPAYFee paymentYear of fee payment: 425 Feb 2013FPAYFee paymentYear of fee payment: 8GirarImagen originalP�gina principal de Google - Sitemap - Descargas masivas de USPTO - Pol�tica de privacidad - Condiciones de servicio - Acerca de Google Patentes - Enviar sugerenciasDatos proporcionados por IFI CLAIMS Patent Services